Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | SCD | O00767 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13070808 | 0.83 | BCHE (0.35) | ROCK2BCHEHTTATMFAAH | |
| SCHEMBL4699798 | 0.82 | ROCK2 (0.36) | ROCK2LMNABCHEHTTATM | |
| SCHEMBL18603273 | 0.82 | KCNH2 (0.34) | ROCK2LMNABCHEHTTATM | |
| SCHEMBL30771246 | 0.82 | AR (0.34) | ROCK2LMNABCHEHTTATM | |
| SCHEMBL23751758 | 0.82 | HTT (0.37) | ROCK2HTTATMGPR119KDM4E | |
| SCHEMBL376224 | 0.81 | L3MBTL1 (0.38) | LMNAATMELANEL3MBTL1KDM4E | |
| SCHEMBL29119613 | 0.81 | ROCK2 (0.33) | ROCK2LMNABCHEHTTATM | |
| SCHEMBL1559237 | 0.80 | ROCK2 (0.34) | ROCK2BCHEHTTATMFAAH | |
| SCHEMBL457060 | 0.79 | ALKBH1 (0.36) | ROCK2BCHEHTTATMFAAH | |
| SCHEMBL29080099 | 0.79 | NR1H2 (0.33) | ROCK2BCHEHTTATMFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346616-A1 | ROCK INHIBITORS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2025-11-13 | — | — | US | disclosed |
| EP-4620528-A2 | BIPYRAZOLE DERIVATIVES AS JAK INHIBITORS | Incyte Holdings Corporation (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-4275756-B1 | BIPYRAZOLE DERIVATIVES AS JAK INHIBITORS | INCYTE HOLDINGS CORP (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20250206726-A1 | BIPYRAZOLE DERIVATIVES AS JAK INHIBITORS | INCYTE HOLDINGS CORPORATION | 2025-06-26 | — | — | US | disclosed |
| EP-4532484-A1 | ROCK INHIBITORS AND USES THEREOF | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2025-04-09 | — | — | EP | disclosed |
| US-12247020-B2 | Bipyrazole derivatives as JAK inhibitors | INCYTE CORPORATION (US) | 2025-03-11 | — | — | US | disclosed |
| CN-119173509-A | ROCK inhibitors and uses thereof | 迪哲(江苏)医药股份有限公司 | 2024-12-20 | — | — | CN | disclosed |
| US-20240150327-A1 | BIPYRAZOLE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION | 2024-05-09 | — | — | US | disclosed |
| US-11905275-B2 | Bipyrazole derivatives as JAK inhibitors | INCYTE CORPORATION (US) | 2024-02-20 | — | — | US | disclosed |
| US-11905275-B2 | Bipyrazole derivatives as JAK inhibitors | INCYTE CORPORATION (US) | 2024-02-20 | — | — | US | disclosed |
| US-20130123281-A1 | Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules | BETA CAT PHARMACEUTICALS, LLC (US) | 2013-05-16 | — | — | US | disclosed |
| US-20120040981-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
| EP-2078016-B1 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2012-02-01 | — | — | EP | disclosed |
| EP-2403857-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2012-01-11 | — | — | EP | disclosed |
| EP-2146997-B1 | SUBSTITUTED FURO[2,3-B]PYRIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2010-11-10 | — | — | EP | disclosed |
| WO-2010101302-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-10 | — | — | WO | disclosed |
| WO-2010046780-A2 | ANTI VIRAL COMPOUNDS | INSTITUT PASTEUR KOREA (KR) | 2010-04-29 | — | — | WO | disclosed |
| EP-2146997-A1 | SUBSTITUTED FURO[2,3-B]PYRIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2010-01-27 | — | — | EP | disclosed |
| US-20080269279-A1 | Substituted furo[2,3-B] pyridine derivatives as cannabinoid-1 receptor modulators | MERCK SHARP & DOHME CORP. | 2008-10-30 | — | — | US | disclosed |
| WO-2008127585-A1 | SUBSTITUTED FURO[2,3-B]PYRIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11905275-B2 | Bipyrazole derivatives as JAK inhibitors | JAK1, JAK2, JAK3 | ROCK2 1139/4885LMNA 4851/4885BCHE 4723/4885 |
| US-20080269279-A1 | Substituted furo[2,3-B] pyridine derivatives as cannabinoid-1 receptor modulators | CNR1, CNR2, FAAH | ROCK2 4342/4885LMNA 1504/4885BCHE 453/4885 |
| US-20120040981-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | CDC7, CDK7, DTYMK | ROCK2 2920/4885LMNA 4174/4885BCHE 3115/4885 |
| US-12247020-B2 | Bipyrazole derivatives as JAK inhibitors | JAK1, JAK2, JAK3 | ROCK2 1139/4885LMNA 4851/4885BCHE 4723/4885 |
| US-20250346616-A1 | ROCK INHIBITORS AND USES THEREOF | ROCK1, ROCK2, RHOA | ROCK2 2/4885LMNA 2579/4885BCHE 1202/4885 |
| US-20250206726-A1 | BIPYRAZOLE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | ROCK2 1139/4885LMNA 4851/4885BCHE 4723/4885 |
| US-20240150327-A1 | BIPYRAZOLE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | ROCK2 1139/4885LMNA 4851/4885BCHE 4723/4885 |
| US-20130123281-A1 | Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules | TBL2, TBL3, TBL1XR1 | ROCK2 1213/4885LMNA 1206/4885BCHE 3735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.